Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ferritin heavy chain 1 pseudogene 6 (FTH1P6)
- Target
- FTH1P6
- Molecular classification
- Processed pseudogene, Long non-coding RNA, ceRNA—competing endogenous RNA
01
Overview
Ferritin heavy chain 1 pseudogene 6 (FTH1P6) is one of a large family of pseudogenes derived from the ferritin heavy chain gene, FTH1. Unlike the canonical protein-coding ferritin heavy chain, FTH1P6 does not encode a functional protein and is classified as a processed pseudogene, likely originating from retrotranspositional events. Recent research has revealed that ferritin pseudogenes like FTH1P6 can serve important non-coding regulatory roles, especially as competitive endogenous RNAs (ceRNAs) that modulate the availability of microRNAs shared with their parental gene. Through this miRNA-related cross-talk, FTH1P6 may indirectly influence the expression of ferritin heavy chain, impacting cellular iron storage and metabolism. This ceRNA activity has been implicated in cell proliferation, survival, and drug resistance in some cancers, such as prostate carcinoma. FTH1P6 is not a classic drug target—no approved therapies act directly on this pseudogene—and its primary significance lies in its regulatory contribution to iron metabolism and related disease networks
- Other names
- Ferritin, heavy polypeptide 1 pseudogene 6FTH1P6ferritin heavy chain pseudogene 6
02
Mechanism of action
Pseudogene-based modulation of gene expression through miRNA sponging or decoy effects (no direct pharmacological mechanisms)
03
Biological functions
Competing endogenous RNA (ceRNA) activity (regulates parental FTH1 gene expression via microRNA binding and modulation)Influences iron metabolism indirectlyPossible role in regulation of cell growth and survival by affecting iron storage proteins in cancer cellular models
04
Disease associations
Cancer (especially regulatory roles in prostate cancer, based on ceRNA effects)Other (potential modulatory effects in diseases where iron metabolism and ferritin expression are implicated, though direct causative roles or biomarker status are unproven)
05
Safety considerations
None documented specific to FTH1P6; as a non-coding RNA pseudogene, targeting it directly has not been explored in clinical therapeutics
06
Biomarkers
FTH1P6 expression levels may have potential as research biomarkers in cancer for functional ceRNA network studies but are not established for patient selection or clinical monitoring
Beyond the preview
Go deeper on Ferritin heavy chain 1 pseudogene 6 (FTH1P6).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ferritin heavy chain 1 pseudogene 6 (FTH1P6).